Abstract
Background Neoadjuvant and adjuvant immune checkpoint inhibitor treatments for non-small cell lung cancer (NSCLC) patients with resectable disease hav......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
